{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:41:24Z","timestamp":1792384884071,"version":"4.4.0"},"reference-count":39,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tirzepatide is a once\u2010weekly glucose\u2010dependent insulinotropic polypeptide and glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large US commercially insured population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study used administrative claims and electronic health records from the Healthcare Integrated Research Database (HIRD). Adults with \u2265\u20091 prescription claim for tirzepatide (for obesity\/overweight, without T2D), between November 2023\u2013June 2024 and continuous medical\/pharmacy enrollment for \u2265\u200912\u2009months pre\u2010index and \u2265\u20096\u2009months post\u2010index were included. Descriptive analyses included baseline demographic and clinical characteristics, treatment patterns and tirzepatide effectiveness (change from baseline in weight, BMI, cardiometabolic risk factors evaluated among persistent individuals) and were stratified by individuals who were GLP\u20101 RA na\u00efve and individuals who switched to tirzepatide from a GLP\u20101 RA obesity medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 22\u2009512 individuals who initiated tirzepatide (mean age: 46\u2009years, 73% female), 55% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912\u2009292) were adherent (PDC \u2265\u200980%) and 68% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915\u2009208) were persistent during the 6\u2010month follow\u2010up period. Of the overall population, 91% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920\u2009554) had \u2265\u20091 obesity\u2010related complication at baseline, with dyslipidaemia, hypertension and anxiety being the most frequent complications. Clinically meaningful mean weight reduction (10.5%;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009808) and numerical reductions in most cardiometabolic risk factors were observed among persistent individuals with available pre\u2010 and post\u2010index measurements, including 12.0% body weight reduction in the GLP\u2010na\u00efve subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over half of US adults with obesity or overweight who initiated tirzepatide were adherent (PDC \u2265\u200980%) and had a favourable persistence profile during a 6\u2010month follow\u2010up period. Persistent users achieved clinically meaningful weight reduction and numerical reductions in most cardiometabolic risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71064","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:12:08Z","timestamp":1786410728000},"page":"9966-9979","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide Persistence and Associated Changes in Clinical Outcomes in\n                    <scp>US<\/scp>\n                    Adults With Obesity or Overweight: A 6\u2010Month Claims Database Analysis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa Hunter","family":"Gibble","sequence":"first","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvika","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Carelon Research  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Mojdami","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vallarino","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Stockbower","sequence":"additional","affiliation":[{"name":"Carelon Research  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6521-1007","authenticated-orcid":false,"given":"Michael","family":"Grabner","sequence":"additional","affiliation":[{"name":"Carelon Research  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Ananth","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-4154","authenticated-orcid":false,"given":"Karishma","family":"Desai","sequence":"additional","affiliation":[{"name":"Carelon Research  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108454"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(25)00355\u20101"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/159281"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)01210\u20108"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883\u2010016\u20100575\u20104"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820934955"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.5126"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889\u2010021\u201012009\u20108"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247307"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13700"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.4158\/ep161365.GL"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897"},{"key":"e_1_2_12_16_1","unstructured":"U.S. Food and Drug Administration \u201cZEPBOUND (Tirzepatide) Injection for Subcutaneous Use \u201d2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s005s006s011s015s019lbl.pdf."},{"key":"e_1_2_12_17_1","unstructured":"U.S. Food and Drug Administration \u201cWEGOVY (semaglutide) Injection for Subcutaneous Use Initial U.S. Approval \u201d2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.11.007"},{"key":"e_1_2_12_19_1","unstructured":"U.S. Food and Drug Administration \u201cMOUNJARO (Tirzepatide) Injection for Subcutaneous Use \u201d2022 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)01200\u2010x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002597\u2010w"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24332"},{"key":"e_1_2_12_25_1","unstructured":"U.S. Food and Drug Administration \u201cFDA Approves First Medication for Obstructive Sleep Apnea\u201d."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16330"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16290"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101636"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.05.003"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.1754"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70110"},{"key":"e_1_2_12_32_1","unstructured":"\u201cMedi\u2010Span Generic Product Identifier (GPI) \u201d2026 https:\/\/assets.contenthub.wolterskluwer.com\/api\/public\/content\/2610220\u2010medi\u2010span\u2010generic\u2010product\u2010identifier\u2010gpi\u2010pdf\u2010f776137639?v=ea3eb174."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27251"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70058"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/annals\u201024\u201002623"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.56"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.216"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:20:33Z","timestamp":1792383633000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/dom.71064"],"URL":"https:\/\/doi.org\/10.1111\/dom.71064","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.71064\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71064\/v4\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}